Supplementary information

Cancer Immunology, Immunotherapy (Submitted in 2021) Kawaguchi et al.

Table S1

| Primer name | Primer sequence | Sense       | Antisense   |
|-------------|-----------------|-------------|-------------|
| CD169       | 5′-ACCTGCCAGCTACTCTCA-3′ | 5′-CCTTTCCAGCAGAAGTTCCAG-3′ |             |
| IL-12       | 5′-AGCACCCAGCTTCTTTCATCAG-3′ | 5′-CTTGAGGGAGAAGTAGGAATGG-3′ |             |
| CXCL10      | 5′-CCAAAGGGATGAGAAGTTCC-3′ | 5′-TCCACTTGTTGTGGCTAC-3′ |             |

Supplementary Table S1 Primers used for RT-qPCR
| Characteristics | Total | CD169 expression | p-value |
|-----------------|-------|------------------|---------|
|                 |       | Low n (%) | High n (%) |
| **Age (years)** |       |           |           |
| Median          | 71.0  | 71.0      | 69.5     |
| Range           | 33-88 | 33-88     | 35-86    |
| ≤65             | 34    | 11 (39.3) | 23 (37.7) |
| >65             | 55    | 17 (60.7) | 38 (62.3) |
| **Gender**      |       |           |           |
| Male            | 53    | 17 (60.7) | 36 (59.0) |
| Female          | 36    | 11 (39.3) | 25 (41.0) |
| **Primary site**|       |           |           |
| Tongue          | 37    | 10 (35.7) | 27 (44.3) |
| Mandible        | 24    | 6 (21.4)  | 18 (29.5) |
| Oral floor      | 11    | 6 (21.4)  | 5 (8.2)   |
| Buccal mucosa   | 10    | 2 (7.1)   | 8 (13.1)  |
| Maxilla         | 7     | 4 (14.3)  | 3 (4.9)   |
| **Clinical T category** | | | | |
| T2              | 44    | 12 (42.9) | 32 (52.5) |
| T3, T4          | 45    | 16 (57.1) | 29 (47.5) |
| **Clinical N stage** | | | | |
| N0              | 27    | 8 (28.6)  | 19 (31.1) |
| N ≥ 1           | 62    | 20 (71.4) | 42 (68.9) |
| **Pathological T category** | | | | |
| T2              | 46    | 11 (39.3) | 35 (57.4) |
| T3, T4          | 43    | 17 (60.7) | 26 (42.6) |
| **Pathological N category** | | | | |
| N0              | 50    | 14 (50.0) | 36 (59.0) |
| N ≥ 1           | 39    | 14 (50.0) | 25 (41.0) |
| **Differentiation** | | | | |
| Well            | 51    | 18 (64.3) | 33 (54.1) |
| Poor, Moderate  | 38    | 10 (35.7) | 28 (45.9) |
| **CD8+ cells/mm² in the tumor** | | | | |
| >1588           | 41    | 6 (21.4)  | 35 (57.4) |
| ≤1588           | 48    | 22 (78.6) | 26 (42.6) |

*Statistically significant results. Abbreviation: OSCC, oral squamous cell carcinoma; LN, lymph node. The average number of CD8+ cells/mm² in the tumor was 1588.

**Supplementary Table S2** Correlation between CD169 expression and clinicopathological factors in 89 patients with OSCC
Supplementary Fig. S1 The effects of naringenin on the proliferation of OSCC cell lines *in vitro*

*a, b,* Viability of NR-S1 and SCC VII cells treated with naringenin. Cells were incubated with various concentrations of naringenin for 24 h. Each experiment was repeated three times. n.s., not significant; data were analyzed through one-way analysis of variance (ANOVA) followed by the Bonferroni/Dunn test.
Supplementary Fig. S2

**The effect of naringenin on tumor growth each day in vivo**

**a, b,** Naringenin significantly suppressed tumor growth of both cell lines. Data were analysed through the Mann-Whitney U test. Values represent the mean ± SD. *p < 0.05, **p < 0.01.